1. Abraham J, Sheppard J, et al. Rethinking transparency and accountability in
medicines regulation in the Unites Kingdom. BMJ 1999
2. Ferriman A. Supply of generic drugs still unreliable. BMJ 2000
3. Beeley N, Berger A. A revolution in drug discovery. BMJ 2000
4. Walton R. Computer support for determining drug dose: systemic review and meta-
analysis. BMJ 1999
5. Dieperink ME, Drogemuller L. Industry-Sponsored Grand Rounds and Prescribing
Behavior. JAMA 2001
6. Beecham L. MPs say the market for generic drugs is “ripe for manipulation”. BMJ
7. Bird D. Improvement in prescribing can be measured only over time. BMJ
8. Jones J. Government orders inquiry as price of generic drugs soars. BMJ
9. Vallee JP Generic drugs and the rights of substitution. Presse Medicale
10. Banahan B, Kolassa EM. A Physician Survey on Generic Drugs and Substitution of
Critical Dose Medications. Arch Intern Med 1997;
11. Meyer GF. Transplant Proceedings. NIH/NLM Medline, HealthSTAR
12. Porro GB, Lazzaroni M, et al. Omeprazole and sucralfate in the treatment of
NSAID-induced gastric and duodenal ulcer. Alimentary Pharmacology & Therapeutics 1998;12(4):355-60.
13. Soo S, Moayyedi P, et al. Pharmacological interventions for non-ulcer dyspepsia.
Cochrane Database of Systematic Reviews 2001;Issue 2.
14. Merck Sharp & Dohme de México. Maduretic (Hidroclorotiazida y Clorhidrato de
15. Loperamide plus simethicone reduced the duration and symptoms of acute diarrhea.
ACP Journal Club 1999
16. Review: Smooth-muscle relaxants treat abdominal pain and loperamide reduces
diarrhea in the irritable bowel syndrome. ACP Journal Club 2001;134(1):18.
17. Domino KB, Anderson EA, et al. Comparative efficacy and safety of ondansetron,
droperidolm and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis. Anesthesia and Analgesia 1999;88(6):1370-9.
18. Peterson W, Cook D. Antisecretory Therapy for Bleeding Peptic Ulcer. American
Medical Association 1998;280(10):877-8.
19. Lysine acetylsalicylate combined with metoclopramide was as effective as
sumatriptan for migraine. ACP Journal Club 1996;124;36.
20. Misoprostol reduced serious NSAID-induced gastrointestinal complications in
rheumatoid arthritis. ACP Journal Club 1996;24:38.
21. Omeprazole healed ulcers and maintained remission better than ranitidine. ACP
22. Omeprazole maintained remission from ulcers better than misoprostol. ACP
23. Yeomans ND, Tulassay Z, et al. A comparison of omeprazole with ranitidine for
ulcers associated with nonsteroidal anti-inflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. New England Journal of Medicine 1998;338(11):719-26.
24. Hawjey CJ, Karrasch JA, et al. Omeprazole compared with misoprostol for ulcers
associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. New England Journal of Medicine 1998;338(11):727-34.
25. Omeprazole was better than cisapride or placebo for controlling heartburn at 4 and 8
weeks. ACP Journal Club 2000;132(2):64.
26. Omeprazole did not reduce mortality, rebleeding, surgery, or transfusion required in
acute upper gastrointestinal bleeding. ACP Journal Club 1992;117:16.
27. Intermittent treatment with ranitidine or omeprazole for 1 year was effective for
gastro-oesophageal reflux disease. Evidence-Based Medicine 1999;4:119.
28. Meta-analysis: Misoprostol reduces NSAID-induced gastrointestinal mucosal
injury. ACP Journal Club 1997;126:36.
29. Misoprostol was most cost-effective if risk for NSAID-related GI events was high.
30. Omeprazole maintained remission from ulcers better than misoprostol. ACP Journal
31. It is unclear whether misoprostol is cost-effective in preventing NSAID gastropathy.
32. It is unclear whether misoprostol is cost-effective in preventing NSAID gastropathy.
33. Bernard B, Grange JD, et al. Antibiotic prophylaxis for the prevention of bacterial
infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29(6):1655-61.
34. Soareas-Weiser K, Brezis M, et al. Antibiotic prophylaxis for bacterial infections in
cirrhotics with gastrointestinal bleeding. The Cochrane Library 2001;(Issue2).
35. Sutherland LR, May GR, et al. Sulfasalazine revisited: a meta-analysis of 5-
aminosalicylic acid in the treatment of ulcerative colitis. Annals of Internal Medicine 1993;118(7):540-9.
36. Dite P, Precechtelova M, et al. Principles of conservative treatment in chronic
pancreatitis. Vnitrni Lekarstvi 2000;46(3):184-6.
37. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355(9198):134-8.
38. Mehl B, Santell J. Projecting future drug expenditures-2000. Am J Health Syst
39. Laxatives and fibre therapies improve bowel movement frequency in adults with
chronic constipation. Evidence-Based Medicine 1997;2:147.
40. Findlay SD, Direct-to-consumer promotion of prescription drugs. Economic
implications for patients, payers and providers. Pharmacoeconomics 2001;19(2):109-19.
41. Mitchell E, Sullivan F. A descriptive feast but an evaluative famine: systemic
review of published articles on primary care computing during 1980-97. BMJ 2001; 322(7281):279-82.
42. Banaham BF, Kolassa EM. A physician survey on generic drugs and substitution of
critical dose medications. Archives of Internal Medicine 1997; 157(18):2080-8.
43. Novakovic J. Validation of a high-performance thin-layer chromatographic method
for trace analysis for some generic drugs affecting gastrointestinal function. Journal of AOAC International 2000; 83(6):1507-16.
44. Ernst ME, Kelly MW, et al. Prescription medication costs: a study of physician
familiarity. Archives of Family Medicine 2000; 9(10):1002-7.
45. Levy R. Utilization of interchangeable generic drugs in Mexico. Salud Pública de
46. Lifshitz A. Generic drugs and medical education. Gaceta Médica de México 2000;
47. Rodríguez-Carranza R, Vidrio H, et al. Generic drugs and medical education.
Gaceta Médica de México 2000; 136(4):341-51.
48. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings
for generic prescription drugs. Journal of the American Pharmaceutical Association 2000; 40(3):378-83.
49. Beecham L. MPs say the market for generic drugs is “ripe for manipulation”. BMJ
50. Mehl B, Santell JP. Projecting future drug expenditures 2000. American Journal of
Health-System Pharmacy 2000; 57(2):129-38.
51. Jones J, Government orders inquiry as price of generic drugs soars. BMJ 1999;
52. Siegel-Itzkovich J. Israel introduces generic drugs scheme. BMJ 1999;
53. McGilveray IJ, Gallicano K. Generic drugs: the Canadian perspective.
Transplantation Proceedings 1999; 31(3A Suppl):16S-18S.
54. Meyer GF. History and regulatory issues of generic drugs. Transplantation
Proceedings 1999; 31(3A Suppl):10S-12S.
55. Palma-Aguirre JA. Generic drugs, bioavailability, and bioequivalence. Gaceta
Medica de Mexico 1998; 134(4):491-4.
57. Objectives of the Policy, Access, and Rational drug use (PAR) team.
58. The Rationale. Access, Quality and Rational Use of Medicines and Essential Drugs.
59. Essential Drugs. WHO Model list (revised December 1999).
60. Captopril. Bioequivalence study of apo-capto 100 mg and Capoten 100 mg.
67. Proposed Revised Drug Strategy Resolution.
68. US compulsory licensing proposal for medicines.
69. USA compulsory licensing proposal for medicines.
70. Brazilian proposed resolutions to World Health Assembly.
71. Revised drug strategy. World Health Organization.2001.
72. Objectives of the Policy, Access, and Rational drug use (PAR) team. Essential
73. Essential Drugs. WHO Model List (revised December 1999).
74. Los Alcaloides de opio (001918).
75. Clindamycin Phosphate. (003129).
78. Dicyclomine Hydrochloride (001048).
83. Lista de Genéricos SSA-2001 (Total 129)
87. Propoxyphene Hydrochloride. Mosby’s Drug consult 2002, Inc.
88. Quinidine Sulfate. Mosby’s Drug consult 2002, Inc.
89. Pentoxifylline. Mosby’s Drug consult 2002, Inc.
90. Propafenone Hydrochloride. Mosby’s Drug consult 2002, Inc.
91. Clinical Studies. MD Consult. Isordil Sublingual Tablets
92. Warfarin Sodiuim. Mosby’s Drug consult 2002, Inc.
93. Norepinephrine Bitartrate. Mosby’s Drug consult 2002, Inc.
94. Tramadol. Mosby’s Drug consult 2002, Inc.
95. Neostigmine Methylsufate. Mosby’s Drug consult 2002, Inc.
96. Naloxone Hydrochloride. Mosby’s Drug consult 2002, Inc.
97. Methylene Blue. Mosby’s Drug consult 2002, Inc.
98. Flumazenil. Mosby’s Drug consult 2002, Inc.
99. Antidotal Flumazenil use the protamine of the 90s. Critical Care Medicine
100.Mathieu-Nolf M Flumazenil use in an emergency department: a survey. J Toxical
101.Acetylcysteine. Mosby’s Drug consult 2002, Inc.
102.Nitroglycerin. Mosby’s Drug consult 2002, Inc.
Natural disaster and Rural Planning The Association of Rural Planning, Japan Head of the symposium organizing committee Scope and Objective: The natural environmental structure of Asia-Pacific Rim and Monsoon Asian reveals vulnerable induced by environmental condition. Additional factors are rapid land cover change and urbanization in the lowlands or river deltas with large expanding
Hair loss is NOT a natural phenomenon. No part of your body should degenerate! If you are experiencing hair loss, it is important to know that you are not genetically cursed. You are simply experiencing the side effects of energy loss. Your body is calling your attention to the fact that your ‘batteries’ are running down and you have not been paying attention. By following the understandin